About Biotangents
Biotangents is a company based in Edinburgh (United Kingdom) founded in 2015. Biotangents has raised $5.62 million across 5 funding rounds from investors including Gov.uk, Scottish Enterprise and Eos. The company has 13 employees as of December 31, 2021. Biotangents offers products and services including AmpliSpec LAB Mastitis and AmpliSpec LAB BVDV. Biotangents operates in a competitive market with competitors including RareCyte, BioLife Solutions, Sequenta, Heska and seqWell, among others.
- Headquarter Edinburgh, United Kingdom
- Employees 13 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biotangents Limited
- Date of Incorporation 21 Jan, 2015
- Jurisdiction PENICUIK, SCOTLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$5.62 M (USD)
in 5 rounds
-
Latest Funding Round
$2.9 M (USD), Series A
Nov 28, 2024
-
Investors
Gov.uk
& 5 more
-
Employee Count
13
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Biotangents
Biotangents offers a comprehensive portfolio of products and services, including AmpliSpec LAB Mastitis and AmpliSpec LAB BVDV.
Rapid identification of bovine mastitis pathogens in cattle samples.
Detection of Bovine Viral Diarrhoea virus in cattle for disease control.
People of Biotangents
Unlock access to complete
Unlock access to complete
Funding Insights of Biotangents
Biotangents has successfully raised a total of $5.62M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $2.9 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Biotangents
Biotangents has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Gov.uk, Scottish Enterprise and Eos.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment in science and technology is managed by Eos.
|
Locked | Locked | Locked | |
|
Private debt investment firm focused on SMEs
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Biotangents
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biotangents
Investment portfolio details for Biotangents
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Biotangents
Detailed financials for Biotangents
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biotangents Comparisons
Peer comparison for Biotangents
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biotangents
Biotangents operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as RareCyte, BioLife Solutions, Sequenta, Heska and seqWell, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of technologies for the analysis of rare and single cells in the blood
|
|
| Locked | Locked | Locked |
Tissue hypothermic storage and cryopreservation freeze media are developed.
|
|
| Locked | Locked | Locked |
Immuno-sequencing products are developed for disease diagnostics and treatment.
|
|
| Locked | Locked | Locked |
Provider of diagnostic solutions for pet care
|
|
| Locked | Locked | Locked |
NGS-based reagents and kits are supplied for life sciences research.
|
|
| Locked | Locked | Locked |
Provider of technologies and solutions genomic research and precision medicine
|
Detailed competitors of Biotangents
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biotangents
Complete news archive for Biotangents
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biotangents
Biotangents was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Biotangents is headquartered in Edinburgh, United Kingdom. It is registered at Edinburgh, Scotland, United Kingdom.
Biotangents is a funded company, having raised a total of $5.62M across 5 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Biotangents is 13.
Biotangents was founded in 2015 in Edinburgh, United Kingdom, within the biotechnology sector focused on veterinary diagnostics. Products are offered for detecting bovine viral diarrhea through RNA-specific sections, utilizing Moduleic Sensing technology. This approach employs modular target-amplifier-reporter constructs to create nucleic acid detectors for animal health applications, supporting diagnostics in the veterinary field.
Biotangents's top competitors include Neogen, Paragon Genomics and RoosterBio.
Biotangents offers AmpliSpec LAB Mastitis and AmpliSpec LAB BVDV.
Biotangents has 6 investors. Key investors include Gov.uk, Scottish Enterprise, Eos, British Business Investments, and Kelvin Capital.